Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-24
1996-12-03
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 82, A61K 3144, C07D47104
Patent
active
055808778
ABSTRACT:
A class of 3,5-dihydro-1H-pyrazolo[3,4-c]quinoline-1,4(2H)-dione derivatives, substituted in the 2-position by an optionally substituted phenyl moiety, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment and/or prevention of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA antagonist.
REFERENCES:
patent: 5071859 (1991-12-01), Knudsen
patent: 5399696 (1995-03-01), Arnold
Helv. Chim. Acta, (1928), vol. 11, p. 242.
Nagarajan et al. "Condensed Heterotricyles: Synthesis of pyrazolo[3,4-c]quinoline derivatives", Indian Jour. of Chem. vol. 31B, 1992, pp. 316-321.
Petracek FJ. in "Principles of Psychopharmacology" W.G. Clark & J. del Giudance eds. (1970) Academic Press NY. pp. 166-167.
Chang Ceila
Huang Evelyn
Merck Sharp & Dohme Ltd.
North Robert J.
Winokur Melvin
LandOfFree
Pyrazolo-quinoline derivatives for treating cerebral ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo-quinoline derivatives for treating cerebral ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo-quinoline derivatives for treating cerebral ischemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-785848